# Prompt Improvements Implementation Summary

**Date:** 2025-12-08  
**Status:** ✅ COMPLETE - All 9 prompt improvements implemented

---

## Overview

All 9 prompt template improvements from `drug_repurposing_prompt_improvements.md` have been successfully implemented to enhance extraction quality, enable organ domain analysis, improve safety classification, and reduce hallucinations.

---

## Implementation Details

### ✅ HIGH PRIORITY (3/3 Complete)

#### 1. **stage2_efficacy.j2** - Organ Domain Classification
- **File:** `src/prompts/templates/case_series/stage2_efficacy.j2`
- **Changes:**
  - Added `organ_domain` field with 11 categories (Musculoskeletal, Mucocutaneous, Renal, Neurological, Hematological, Cardiopulmonary, Immunological, Systemic, Gastrointestinal, Ocular, Constitutional)
  - Added `is_validated_instrument` boolean flag
  - Added `instrument_quality_tier` (1-3 scale: 1=gold standard, 2=validated PRO, 3=investigator-assessed)
  - Added comprehensive classification guides for organ domains and instrument quality tiers
- **Schema Updates:** `DetailedEfficacyEndpoint` in `src/models/case_series_schemas.py` (lines 149-151)

#### 2. **stage3_safety.j2** - MedDRA-Aligned Categories
- **File:** `src/prompts/templates/case_series/stage3_safety.j2`
- **Changes:**
  - Replaced free-text `event_category` with structured `category_soc` field
  - Added 13 MedDRA-aligned categories (Infections, Malignancies, Cardiovascular, Thromboembolic, Hepatotoxicity, Cytopenias, GI Perforation, Hypersensitivity, Neurological, Pulmonary, Renal, Death, Metabolic)
  - Added subtype fields: `infection_type`, `malignancy_type`, `cv_type`, `thromboembolic_type`
  - Added `is_class_effect` boolean for known drug class effects
  - Added classification guides and known class effects for JAK inhibitors, IL-1 inhibitors, Anti-CD20, TNF inhibitors
- **Schema Updates:** `DetailedSafetyEndpoint` in `src/models/case_series_schemas.py` (lines 183-189)

#### 3. **main_extraction.j2** - Extraction Confidence Scoring
- **File:** `src/prompts/templates/case_series/main_extraction.j2`
- **Changes:**
  - Added `extraction_confidence` object with 6 fields:
    - `disease_certainty` (High/Medium/Low)
    - `n_patients_certainty` (High/Medium/Low)
    - `efficacy_data_quality` (Complete/Partial/Sparse)
    - `safety_data_quality` (Complete/Partial/Sparse)
    - `data_source` (Abstract only/Full text/Tables available)
    - `limiting_factors` (array of issues)
  - Added detailed scoring guide for each field
- **Schema Updates:** 
  - New `ExtractionConfidence` class in `src/models/case_series_schemas.py` (lines 52-59)
  - Added `extraction_confidence_detail` field to `CaseSeriesExtraction` (line 229)

---

### ✅ MEDIUM PRIORITY (4/4 Complete)

#### 4. **filter_papers.j2** - Chain-of-Thought Reasoning
- **File:** `src/prompts/templates/case_series/filter_papers.j2`
- **Changes:**
  - Added systematic evaluation framework with 4 explicit inclusion criteria
  - Added YES/NO decision tree for each criterion (Patient Count, Clinical Outcomes, Off-Label Use, Original Data)
  - Added instruction to provide reasoning in "reason" field referencing which criteria were met/failed

#### 5. **extract_epidemiology.j2** - Source Quality Ranking
- **File:** `src/prompts/templates/case_series/extract_epidemiology.j2`
- **Changes:**
  - Added `source_quality` field (Primary/Secondary/Estimate)
  - Added `data_year` field (integer)
  - Added `geographic_scope` field (US/Global/Regional)
  - Added `confidence` field (High/Medium/Low)
  - Added `notes` field for caveats
  - Added classification guides for source quality and confidence scoring
- **Schema Updates:** `EpidemiologyData` in `src/models/case_series_schemas.py` (lines 254-260)

#### 6. **standardize_diseases.j2** - Explicit Mapping Hints
- **File:** `src/prompts/templates/case_series/standardize_diseases.j2`
- **Changes:**
  - Added 30+ common abbreviation mappings (AA→Alopecia Areata, AD→Atopic Dermatitis, etc.)
  - Added Type I Interferonopathy groupings (CANDLE, SAVI, AGS)
  - Added "KEEP DISTINCT" section for diseases that should not be merged
  - Covers dermatology, rheumatology, gastroenterology, and rare autoinflammatory conditions

#### 7. **json_rules.j2** - Strengthen JSON Enforcement
- **File:** `src/prompts/templates/case_series/_partials/json_rules.j2`
- **Changes:**
  - Expanded from 4 lines to 34 lines
  - Added comprehensive guidelines covering:
    - Output format (JSON only, no markdown)
    - Null value handling (use null, not "null" or "N/A")
    - Data types (strings in quotes, numbers/booleans unquoted)
    - String escaping (quotes, newlines, backslashes)
    - Array formatting (empty arrays as [], not null)
    - Extraction principles (extract what's stated, don't infer)

---

### ✅ LOWER PRIORITY (2/2 Complete)

#### 8. **stage1_sections.j2** - Table Detection Patterns
- **File:** `src/prompts/templates/case_series/stage1_sections.j2`
- **Changes:**
  - Added common table/figure patterns section with examples for:
    - Baseline/Demographics tables (Table 1 patterns)
    - Efficacy tables (Table 2-3 patterns with response rates, disease scores)
    - Safety tables (Table 3-4 patterns with AE data)
    - Efficacy figures (Kaplan-Meier, waterfall plots, spider plots)
    - Supplementary materials (Supplementary Table S1, Extended Data)

#### 9. **calculate_tam.j2** - Therapeutic Area Benchmarks
- **File:** `src/prompts/templates/case_series/calculate_tam.j2`
- **Changes:**
  - Added therapeutic area benchmarks for 6 categories:
    - Autoimmune - Dermatology ($30-60K/yr, 60-80% penetration)
    - Autoimmune - Rheumatology ($50-80K/yr, 50-70% penetration)
    - Rare Autoimmune ($80-200K/yr, 30-50% penetration)
    - Ultra-Rare (<5K patients, $200-500K/yr)
    - Lupus (SLE/LN, $40-80K/yr, 40-60% penetration)
  - Added reference drug launches (Dupixent, Rinvoq, Skyrizi, Taltz, Saphnelo, Lupkynis)
  - Added treatment funnel defaults (diagnosis rates, treatment rates, LOT reach)
  - Added calculation template with worked example

---

## Schema Updates Summary

### Modified Files:
1. **`src/models/case_series_schemas.py`**
   - Added `ExtractionConfidence` class (lines 52-59)
   - Updated `DetailedEfficacyEndpoint` with organ domain fields (lines 149-151)
   - Updated `DetailedSafetyEndpoint` with MedDRA-aligned fields (lines 183-189)
   - Updated `CaseSeriesExtraction` with `extraction_confidence_detail` (line 229)
   - Updated `EpidemiologyData` with source quality fields (lines 254-260)

---

## Testing Status

- ✅ All prompt templates updated
- ✅ All schemas updated to support new fields
- ⏳ **NEXT STEP:** Run agent with updated prompts to verify extraction works correctly

---

## Expected Benefits

1. **Better Efficacy Scoring:** Organ domain classification enables domain-specific weighting
2. **Improved Safety Analysis:** MedDRA-aligned categories enable systematic safety signal detection
3. **Quality Transparency:** Extraction confidence scoring shows data quality limitations
4. **Reduced Hallucinations:** Stronger JSON rules and chain-of-thought reasoning
5. **Better Disease Standardization:** Explicit abbreviation mappings reduce ambiguity
6. **More Accurate TAM:** Therapeutic area benchmarks provide realistic market sizing

